These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 7610692)

  • 1. Budesonide in glucocorticoid dependent chronic active Crohn's disease; a pilot study.
    Novacek G; Kleinberger M; Vogelsang H; Moser G; Lochs H
    Z Gastroenterol; 1995 May; 33(5):251-4. PubMed ID: 7610692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of active Crohn's ileocolitis with oral pH-modified budesonide. Germany Budesonide Study Group.
    Caesar I; Gross V; Roth M; Andus T; Schmidt C; Raedsch R; Weber A; Gierend M; Ewe K; Schölmerich J
    Z Gastroenterol; 1995 May; 33(5):247-50. PubMed ID: 7610691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of active and postactive ileal and colonic Crohn's disease with oral pH-modified-release budesonide. German Budesonide Study Group.
    Caesar I; Gross V; Roth M; Andus T; Schmidt C; Raedsch R; Weber A; Gierend M; Ewe K; Schölmerich J
    Hepatogastroenterology; 1997; 44(14):445-51. PubMed ID: 9164517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of budesonide with prednisolone for active Crohn's disease.
    Rutgeerts P; Löfberg R; Malchow H; Lamers C; Olaison G; Jewell D; Danielsson A; Goebell H; Thomsen OO; Lorenz-Meyer H
    N Engl J Med; 1994 Sep; 331(13):842-5. PubMed ID: 8078530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn's disease. German/Austrian Budesonide Study Group.
    Gross V; Andus T; Caesar I; Bischoff SC; Lochs H; Tromm A; Schulz HJ; Bär U; Weber A; Gierend M; Ewe K; Schölmerich J
    Eur J Gastroenterol Hepatol; 1996 Sep; 8(9):905-9. PubMed ID: 8889459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States.
    Tremaine WJ; Hanauer SB; Katz S; Winston BD; Levine JG; Persson T; Persson A;
    Am J Gastroenterol; 2002 Jul; 97(7):1748-54. PubMed ID: 12135030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group.
    Greenberg GR; Feagan BG; Martin F; Sutherland LR; Thomson AB; Williams CN; Nilsson LG; Persson T
    N Engl J Med; 1994 Sep; 331(13):836-41. PubMed ID: 8078529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Crohn disease: prevention and drug therapy].
    Gross V; Andus T; Schölmerich J
    Chirurg; 1995 Aug; 66(8):757-63. PubMed ID: 7587538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group.
    Campieri M; Ferguson A; Doe W; Persson T; Nilsson LG
    Gut; 1997 Aug; 41(2):209-14. PubMed ID: 9301500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials.
    Sandborn WJ; Löfberg R; Feagan BG; Hanauer SB; Campieri M; Greenberg GR
    Am J Gastroenterol; 2005 Aug; 100(8):1780-7. PubMed ID: 16086715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maintenance treatment with budesonide 6 mg versus 9 mg once daily in patients with Crohn's disease in remission.
    de Jong DJ; Bac DJ; Tan G; de Boer SY; Grabowsky IL; Jansen JB; Greinwald R; Naber TH
    Neth J Med; 2007 Oct; 65(9):339-45. PubMed ID: 17954953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of oral topically acting glucocorticosteroids in the treatment of inflammatory bowel disease.
    Rutgeerts P
    Mediators Inflamm; 1998; 7(3):137-40. PubMed ID: 9705597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defining the optimal response criteria for the Crohn's disease activity index for induction studies in patients with mildly to moderately active Crohn's disease.
    Thia KT; Sandborn WJ; Lewis JD; Loftus EV; Feagan BG; Steinhart AH; Hanauer SB; Persson T; Sands BE
    Am J Gastroenterol; 2008 Dec; 103(12):3123-31. PubMed ID: 18786111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial.
    Hanauer S; Sandborn WJ; Persson A; Persson T
    Aliment Pharmacol Ther; 2005 Feb; 21(4):363-71. PubMed ID: 15709986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease.
    Mantzaris GJ; Petraki K; Sfakianakis M; Archavlis E; Christidou A; Chadio-Iordanides H; Triadaphyllou G
    Clin Gastroenterol Hepatol; 2003 Mar; 1(2):122-8. PubMed ID: 15017504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of cyclosporine, azathioprine and prednisolone for perianal fistulas in Crohn's disease.
    Hinterleitner TA; Petritsch W; Aichbichler B; Fickert P; Ranner G; Krejs GJ
    Z Gastroenterol; 1997 Aug; 35(8):603-8. PubMed ID: 9297775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of topically and systemically active steroids on circulating leukocytes in Crohn's disease.
    Tillinger W; Gasche C; Reinisch W; Lichtenberger C; Bakos S; Dejaco C; Moser G; Vogelsang H; Gangl A; Lochs H
    Am J Gastroenterol; 1998 Oct; 93(10):1848-53. PubMed ID: 9772043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison between high dose 5-aminosalicylic acid and 6-methylprednisolone in active Crohn's ileocolitis. A multicenter randomized double-blind study. German 5-ASA Study Group.
    Gross V; Andus T; Fischbach W; Weber A; Gierend M; Hartmann F; Schölmerich J
    Z Gastroenterol; 1995 Oct; 33(10):581-4. PubMed ID: 7502549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term treatment of high intestinal output syndrome with budesonide in patients with Crohn's disease and ileostomy.
    Ecker KW; Stallmach A; Löffler J; Greinwald R; Achenbach U
    Dis Colon Rectum; 2005 Feb; 48(2):237-42. PubMed ID: 15714248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical relevance of serum interleukin-6 in Crohn's disease: single point measurements, therapy monitoring, and prediction of clinical relapse.
    Reinisch W; Gasché C; Tillinger W; Wyatt J; Lichtenberger C; Willheim M; Dejaco C; Waldhör T; Bakos S; Vogelsang H; Gangl A; Lochs H
    Am J Gastroenterol; 1999 Aug; 94(8):2156-64. PubMed ID: 10445543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.